VictorSSloanMD

Rheumatology • New Brunswick, NJ

Physician

Join to view full profile

Dr. Sloan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sloan's full profile

Already have an account?

Office
125 Paterson St
Division of Rheumatology
New Brunswick, NJ 08901
Phone+1 732-235-6583

Fax+1 732-235-6526

Education & Training

University of California (San Francisco)Fellowship, Rheumatology, 1993 - 1994
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1989 - 1991
New York Medical CollegeClass of 1989

Certifications & Licensure

CA State Medical License 1992 - Present
NJ State Medical License 1994 - 2023
PA State Medical License 1996 - 1998
NY State Medical License 1990 - 1996
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2004
Fellow American College of Rheumatology

Clinical Trials

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy Start of enrollment: 2005 Jan 01
Completed
Phase 2, Phase 3

Publications & Presentations

PubMed

42 citations
Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheu...
Patrice Matchaba, Xavier Gitton, Gerhard Krammer, Elena Ehrsam, Victor S. Sloan
Clinical Therapeutics. 2005-08-01
54 citations
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Eric Sheldon, André D. Beaulieu, Zorba Paster, Dipen Dutta, Sue Yu
Clinical Therapeutics. 2005-01-01
37 citations
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Roy Fleischmann, Eric Sheldon, José A. Maldonado-Cocco, Dipen Dutta, Sue Yu
Clinical Rheumatology. 2006-02-01

Press Mentions

Chronic Opioid Use May Be Common in Patients with Ankylosing SpondylitisJune 11th, 2019

Professional Memberships

American College of Physicians - ACP
Fellow